Magdy Elserafy
Overview
Explore the profile of Magdy Elserafy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
17
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El-Sayed M, Elserafy M, Raziky M, Elakel W, Saad Y, Fayad T, et al.
Arab J Gastroenterol
. 2023 Feb;
24(1):29-33.
PMID: 36813580
Background And Study Aims: Hepatitis C virus (HCV) prevalence inchronic kidney disease (CKD) patients is significantly higher than in the general population. This study evaluated the efficacy and safety of...
2.
Role of endoscopic ultrasound and cyst fluid tumor markers in diagnosis of pancreatic cystic lesions
Okasha H, Abdellatef A, Elkholy S, Mogawer M, Yosry A, Elserafy M, et al.
World J Gastrointest Endosc
. 2022 Aug;
14(6):402-415.
PMID: 35978716
Background: Pancreatic cystic lesions (PCLs) are common in clinical practice. The accurate classification and diagnosis of these lesions are crucial to avoid unnecessary treatment of benign lesions and missed opportunities...
3.
Naguib G, Farid A, Hassan M, Elshafie A, Shazly Y, Shaker M, et al.
Arab J Gastroenterol
. 2021 Sep;
22(4):285-291.
PMID: 34531135
Background And Study Aims: Chronic hepatitis C virus (HCV) infection has always been identified as a major health threat and a potential cause of liver cirrhosis, portal hypertension, and other...
4.
Nasser M, Zayed N, Gamal Eldeen H, Abdo M, Kabara Y, Elserafy M
Arab J Gastroenterol
. 2021 Jun;
22(2):151-157.
PMID: 34090829
Background And Study Aims: Hepatitis B (HB) surface antigen (HBsAg) levels can predict clinical and treatment outcomes in chronic HB virus (HBV) infection. We aimed to compare the performance of...
5.
Darweesh S, ElSaeed K, Omar H, Raziky M, Elakel W, Elserafy M, et al.
Expert Rev Gastroenterol Hepatol
. 2019 Jun;
13(9):907-914.
PMID: 31173527
Evaluation of the efficacy and safety of sofosbuvir/daclatasvir/ribavirin (SOF/DCV/RBV) in treating non-sustained virological responders (non-SVR12) to prior sofosbuvir-based therapy, in absence of RAS testing in mass treatment, and determination of...
6.
Kassas M, Alboraie M, Omar H, El Latif Y, Algaber M, El Tahan A, et al.
J Med Virol
. 2019 Apr;
94(2):667-674.
PMID: 30950069
Introduction And Aims: Treatment of hepatitis C virus (HCV) genotype 4 patient with fixed dose combination of ombitasvir-paritaprevir-ritonavir plus ribavirin (OBV/rPTV/RBV) has been proven efficacy and safety in many clinical...
7.
Eletreby R, Said M, Abdellatif Z, Saad Y, Elserafy M, Dabes H, et al.
Hepatol Int
. 2018 Feb;
12(2):143-148.
PMID: 29445911
Background: HCV is associated with several extra hepatic diseases including thyroid dysfunction. This study aims at evaluating prevalence of thyroid dysfunction and its possible predictors in a large cohort of...
8.
Elbaz T, Elserafy M, Elakel W, Mohey M, Abdo M, Hassany M, et al.
J Interferon Cytokine Res
. 2017 Aug;
37(8):348-353.
PMID: 28777714
Viral hepatitis is a serious problem worldwide that was under-recognized till recently. The prevalence of chronic hepatitis C virus (HCV) is estimated to be 180 million people worldwide. Treatment of...